Recent News

• 08.06.2026 - Immunocore reports second quarter financial results and provides a business update
• 07.30.2026 - Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
• 05.31.2026 - Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
• 05.06.2026 - Immunocore reports first quarter financial results and provides a business update
• 04.19.2026 - KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
• 04.06.2026 - Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
• 03.17.2026 - Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
• 03.03.2026 - Immunocore to present at upcoming investor conferences
• 02.25.2026 - Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
• 02.18.2026 - Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2026

Recent Filings

• 08.06.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - 8-K Current report
• 08.06.2026 - EX-99.1 EX-99.1
• 05.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.28.2026 - 4 Statement of changes in beneficial ownership of securities